Today: 9 April 2026
ServiceNow stock price rises again ahead of NOW earnings — what could move shares nextServiceNowServiceNow stock price rises again ahead of NOW earnings — what could move shares next
26 January 2026
1 min read

ServiceNow stock price rises again ahead of NOW earnings — what could move shares nextServiceNowServiceNow stock price rises again ahead of NOW earnings — what could move shares next

New York, January 26, 2026, 12:16 (EST) — Regular session.

  • ServiceNow shares were up about 1.6% in midday trading as investors positioned ahead of earnings.
  • Analysts are zeroing in on subscription growth and backlog metrics for signs of demand.
  • ServiceNow reports after Wednesday’s close, with a conference call set for 5 p.m. ET.

ServiceNow, Inc. (NOW) shares rose about 1.6% to $135.29 by 12:16 p.m. EST on Monday, after ending the previous session at $133.11. The stock traded between $133.18 and $136.14, with about 6.1 million shares changing hands.

The workflow software maker reports results after the close on Wednesday, landing in a week packed with mega-cap tech earnings and a Federal Reserve rate decision. For investors still debating how much to pay for growth tied to AI-driven automation, guidance matters more than the headline beat.

U.S. stocks were higher as markets geared up for the Fed and big earnings, with the S&P 500 and Nasdaq up about 0.5% and 0.6% in late morning trading, Reuters reported. “This week’s lineup of megacap earnings should help shape sentiment around the AI trade,” Chris Larkin at E*Trade from Morgan Stanley said. Reuters

Bernstein SocGen Group analyst Peter Weed reiterated an Outperform rating and pointed to upside catalysts from generative AI, tools that generate text and other content. “ServiceNow may even see incremental H2 revenue upside,” Weed wrote in an investor note. Finviz

BMO Capital said it expects the quarter could come in slightly better than anticipated on a constant-currency basis — excluding exchange-rate swings — for subscription revenue and “current remaining performance obligations” (cRPO), a measure of contracted revenue still to be recognized. Jefferies also expects a modest beat on constant-currency cRPO and subscription revenue, while BMO cited broader “multiple compression” in software stocks as a drag on valuations. Finviz

That sets up a familiar checklist: subscription growth, cRPO, and the tone around 2026 demand. Investors will be listening for whether large customers are still expanding deployments, or if deals are slipping out as budgets get tighter.

ServiceNow has said it will release fourth-quarter and full-year 2025 results after the close on January 28, followed by a conference call and webcast at 2 p.m. Pacific (5 p.m. ET). newsroom.servicenow.com

The stock’s move came alongside gains in other enterprise software names, with Salesforce up about 0.4%, Workday up about 1.3%, Oracle up about 4.0% and SAP up about 3.6%.

But the setup cuts both ways. A cautious outlook, or any stumble in backlog metrics, could snap the rebound, especially if the Fed leans hawkish and rate expectations push higher.

Beyond the numbers, traders will sift management’s comments for signs of traction in AI features meant to automate IT, customer support and other workflow-heavy tasks — and whether customers are paying up for them.

Next up: ServiceNow’s earnings after Wednesday’s close, with the Federal Reserve statement due the same day.

Stock Market Today

  • AbbVie's Humira Launch on TrumpRx with 86% Discount Sparks Valuation Questions
    April 9, 2026, 9:02 AM EDT. AbbVie (NYSE:ABBV) has introduced Humira on the TrumpRx platform at an 86% discount under a White House pricing deal aiming to reduce patient costs and widen drug access. This marks a significant US pricing strategy shift post exclusivity for Humira, a key immunology therapy driving substantial revenue. The stock trades near $206.69, about 20% below analyst targets and 43.8% under fair value estimates. The deep discount could alter patient volume, payer ties, and pricing benchmarks in government-linked drug programs. AbbVie's revenue exposure of $61.2 billion and a high price-to-earnings ratio of 87.3 place focus on potential impacts to cash flow and dividends amid its debt load. Investors should monitor reactions from payers, competitors, and capital markets to this pricing shift that could redefine AbbVie's US market dynamics.

Latest article

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

9 April 2026
Brent crude rebounded 3% Thursday despite a U.S.-Iran ceasefire, with the Strait of Hormuz still nearly shut and only one oil-products tanker passing in 24 hours. U.S. gasoline averaged $4.166 a gallon on April 9, and AAA said prices could drop slowly. North Sea Forties crude hit a record $146.43 a barrel. The U.S. EIA expects Hormuz flows may take months to recover.
CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

9 April 2026
CoreWeave said Meta Platforms committed about $21 billion for AI cloud capacity through December 2032. Shares rose 4.3% to $88.90 in premarket trading after the announcement. The deal follows an $8.5 billion loan facility and a $1.25 billion senior notes offering. CoreWeave reported $5.13 billion in 2025 revenue and ended December with a $66.8 billion backlog.
NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

9 April 2026
TrendForce said April 8 that Nvidia’s Rubin AI chip shipments may be delayed by HBM4 memory qualification and cooling demands, shifting over 70% of 2026 high-end GPU volume to the current Blackwell line. Rubin’s projected share dropped to 22%. Samsung began shipping HBM4 to Nvidia in February, but SK Hynix and Micron face qualification delays. Broadcom signed a long-term deal to develop Google’s TPUs through 2031.
Lam Research stock jumps near 3% as Evercore lifts target — what LRCX investors watch next
Previous Story

Lam Research stock jumps near 3% as Evercore lifts target — what LRCX investors watch next

Applied Materials stock slips midday as chip-equipment trade turns cautious ahead of ASML results
Next Story

Applied Materials stock slips midday as chip-equipment trade turns cautious ahead of ASML results

Go toTop